Is Hydrocortisone butyrate registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 4 valid registrations of Hydrocortisone butyrate, including LOCOID CREAM 0.1% (0.1 %, Cream, SAR 11.40); LOCOID LIPO CREAM 0.1% (0.1 %, Cream, SAR 11.40); LOCOID LOTION 0.1% (0.1 %, Cutaneous liquid, SAR 19.80); LOCOID OINT 0.1% (0.1 %, Ointment, SAR 9.45).

Is Hydrocortisone butyrate approved by the US FDA?

Drugs@FDA lists 15 application product lines for Hydrocortisone butyrate, including LOCOID (Prescription); LOCOID (Prescription); LOCOID LIPOCREAM (Prescription); HYDROCORTISONE BUTYRATE (Prescription); HYDROCORTISONE BUTYRATE (Prescription).

Are there safety signals or safety updates for Hydrocortisone butyrate?

US FDA: 1 entry (latest 2024-10-03).

Active substance

Hydrocortisone butyrate

SFDA 7
US FDA 15
NHS prices 2
Safety 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
LOCOID CREAM 0.1%	0.1 %	Cream · Topical	1 Tube	SAR 11.40	NCE · OTC	CHEPLAPHARM Arzneimittel GmbH	Valid
LOCOID LIPO CREAM 0.1%	0.1 %	Cream · Topical	1 Tube	SAR 11.40	NCE · OTC	CHEPLAPHARM Arzneimittel GmbH	Valid
LOCOID LOTION 0.1%	0.1 %	Cutaneous liquid · Topical	1 Tube	SAR 19.80	NCE · OTC	CHEPLAPHARM Arzneimittel GmbH	Valid
LOCOID OINT 0.1%	0.1 %	Ointment · Topical	1 Tube	SAR 9.45	NCE · OTC	CHEPLAPHARM Arzneimittel GmbH	Valid
LOCOID CREAM 0.1%	0.1 %	Cream · Topical	1 Tube	SAR 22.65	NCE · OTC	ASTELLAS PHARMA	Withdrawn by MAH · Not Marketed
LOCOID LIPO CREAM 0.1%	0.1 %	Cream · Topical	1 Tube	SAR 22.65	NCE · OTC	ASTELLAS PHARMA	Withdrawn by MAH · Not Marketed
LOCOID LOTION 0.1%	0.1 %	Cutaneous liquid · Topical	1 Tube	SAR 19.80	NCE · OTC	ASTELLAS PHARMA	Withdrawn by MAH · Not Marketed

Indications — CHI Daman Drug Formulary

ANAL FISSURE; BEHCET DISEASE; ECZEMA; GRAFT VERSUS HOST DISEASE; PSORIASIS; VITILIGO

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
LOCOID	0.1%	cream · topical	BAUSCH	Prescription	31 Mar 1982
LOCOID	0.1%	solution · topical	BAUSCH	Prescription	25 Feb 1987
LOCOID LIPOCREAM	0.1%	cream · topical	PRECISION DERMAT	Prescription	8 Sep 1997
HYDROCORTISONE BUTYRATE	0.1%	solution · topical	TARO PHARM INDS	Prescription	14 Jan 2004
HYDROCORTISONE BUTYRATE	0.1%	ointment · topical	TARO	Prescription	27 Dec 2004
HYDROCORTISONE BUTYRATE	0.1%	cream · topical	TARO PHARM INDS	Prescription	3 Aug 2005
HYDROCORTISONE BUTYRATE	0.1%	lotion · topical	THE J MOLNER	Prescription	21 Nov 2017
HYDROCORTISONE BUTYRATE	0.1%	cream · topical	ACTAVIS MID ATLANTIC	Prescription	8 Dec 2017
HYDROCORTISONE BUTYRATE	0.1%	lotion · topical	LUPIN	Prescription	17 Aug 2018
LOCOID	0.1%	ointment · topical	PRECISION DERMAT	Discontinued	29 Oct 1982
LOCOID	0.1% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	lotion · topical	BAUSCH	Discontinued	18 May 2007
HYDROCORTISONE BUTYRATE	0.1%	cream · topical	GLENMARK PHARMS LTD	Discontinued	27 Sep 2013
LOCOID	0.1%	cream · topical	YAMANOUCHI	Discontinued
LOCOID	0.1%	ointment · topical	YAMANOUCHI	Discontinued
LOCOID	0.1%	solution · topical	YAMANOUCHI	Discontinued

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
NHS Drug Tariff	Hydrocortisone butyrate 0.1% cream	£4.93	100 gram	1 Oct 2026
NHS Drug Tariff	Hydrocortisone butyrate 0.1% scalp lotion	£6.83	100 ml	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

US FDA 3 Oct 2024 LOCOID LIPOCREAM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for hydrocortisone butyrate →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.